Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | CASP4 | P49662 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | CASP9 | P55211 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1946351 | 0.84 | ALDH1A1 (0.47) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL1944324 | 0.83 | ALDH1A1 (0.44) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL1945643 | 0.83 | HTT (0.47) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL1946695 | 0.81 | ALDH1A1 (0.35) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL30930904 | 0.81 | LMNA (0.47) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL1943444 | 0.80 | ALDH1A1 (0.45) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL1944816 | 0.79 | ALDH1A1 (0.40) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL15337529 | 0.79 | HTT (0.41) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL1944903 | 0.78 | CYP19A1 (0.43) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL18911147 | 0.77 | BRPF1 (0.32) | CASP1NR1H2NR1H3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732070-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732070-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732070-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170152246-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2017-06-01 | — | — | US | disclosed |
| US-20170152246-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2017-06-01 | — | — | US | disclosed |
| US-20170152246-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2017-06-01 | — | — | US | disclosed |
| EP-2507227-B1 | TETRAZOLONES AS PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2507227-B1 | TETRAZOLONES AS PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2507227-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | Rigel Pharmaceuticals, Inc. (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011068898-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011068898-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20110130415-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
| US-20110130415-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
| US-20110130415-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130415-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | CASP1 4276/4885CASP3 3560/4885CASP4 4056/4885 |
| US-20170152246-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | CASP1 4276/4885CASP3 3560/4885CASP4 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.